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Aims: It is known that type 2 diabetic patients are at high risk of atrial ﬁbrillation (AF). However, the early
echocardiographic determinants of AF vulnerability in this patient population remain poorly known.
Methods: We followed-up for 2 years a sample of 180 consecutive outpatients with type 2 diabetes, whowere free
from AF and ischemic heart disease at baseline. All patients underwent a baseline echocardiographic-Doppler
evaluationwith tissueDoppler and 2-D strain analysis. Standard electrocardiogramswere performed twice per year,
and a diagnosis of incident AF was conﬁrmed in affected patients by a single cardiologist.
Results: Over the 2-year follow-up period, 14 (7.8%) patients developed incident AF. In univariate analyses,
echocardiographic predictors of new-onset AF were greater indexed cardiac mass, larger indexed left atrial volume
(LAVI), lower global longitudinal strain (LSSYS), lower global diastolic strain rate during early phase of diastole (SRE),
lower global diastolic strain rate during late phase of diastole (SRL), and higher E/SRE ratio. Multivariate logistic
regression analysis showed that lower LSSYS remained the only signiﬁcant predictor of new-onset AF (adjusted-odds
ratio 1.63, 95%CI 1.17–2.27; p b 0.005) after adjustment for age, sex, diabetes duration, indexed cardiac mass and
LAVI. Results were unchanged even after adjustment for body mass index, hypertension and glycemic control.
Conclusions: This is theﬁrst prospective study to show that early LSSYS impairment independently predicts the risk of
new-onset AF in type 2diabetic patientswith preserved ejection fraction andwithout ischemic heart disease. Future
larger prospective studies are needed to conﬁrm these ﬁndings.© 2017 Elsevier Inc. All rights reserved.1. Introduction
Type 2 diabetes mellitus (T2DM) is a major global health problem
with an estimated worldwide prevalence of 2.8% in 2000, projected to
increase to approximately 4.5% in 2030 (Wild, Roglic, Green, Sicree, &
King, 2004). Patients with T2DM have at least twice the risk of
developing cardiovascular complications and death compared with
subjects without diabetes (Huxley, Barzi, & Woodward, 2006).
Similarly, there is now convincing evidence of progressive
increases in prevalence, incidence, and morbidity and mortality
related to atrial ﬁbrillation (AF) between 1990 and 2010 worldwide,Diabetes and Metabolism,
aliera Universitaria Integrata,
r).with signiﬁcant public health implications (Benjamin et al., 1998;
Chungh et al., 2014; Miyasaka et al., 2006).
AF is very common in patients with T2DM with estimates of
prevalence which range from 5 to 8% in primary care setting (Du et al.,
2009; Ostgren, Merlo, Råstam, & Lindblad, 2004) to 15% in
hospitalized patients (Movahed, Hashemzadeh, & Jamal, 2005). It
has been estimated that the presence of T2DM, irrespective of
coexisting comorbidities, confers an approximately 1.5-fold increased
risk of new-onset AF (Anonymous, 2014; Huxley, Filion, Konety, &
Alonso, 2011).
The increased risk of new-onset AF observed in patients with T2DM is
likely due to coexisting comorbidities, such as obesity, hypertension and
ischemic heart disease (IHD) (Anonymous, 2014). However, convincing
evidence also suggests that T2DM per se may affect cardiac function and
structure, irrespective of these comorbidities, consistent with the
existence of a distinct diabetic cardiomyopathy (Bonapace et al., 2015;
Fang et al., 2003;Kadappu et al., 2012; Kannel, Hjortland, &Castelli, 1974).
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provides useful information about the presence of early left
ventricular (LV) systolic dysfunction, which is unmasked by global
longitudinal strain (LSSYS) alterations that may be predictive of
cardiovascular events and death in people with diabetes before the
appearance of overt diabetic cardiomyopathy (Fang et al., 2003;
Nakai, Takeuchi, Nishikage, Lang, & Otsuji, 2009; Ng et al., 2009). In
community-based studies, impaired LSSYS predicted major cardiovas-
cular events and improved cardiovascular risk stratication in subjects
with normal LV ejection fraction (Russo et al., 2014; Stanton, Leano, &
Marwick, 2009). Recently, the Northern Manhattan Study showed
that impaired LSSYS independently predicted also the risk of
new-onset AF in the elderly population and improved AF risk
stratiﬁcation in addition to established risk factors and echocardio-
graphic parameters, like left atrial volume (Russo et al., 2015).
Given the growing epidemiological relevance of T2DM and AF
worldwide, the identiﬁcation of early echocardiographic predictors of
AF in T2DM is of paramount importance to further improve the
prevention and treatment strategies aimed at reducing the risk of
morbidity and mortality attributed to AF in this particularly high-risk
patient population.
Currently, no data are available regarding a link between early
LSSYS impairment and risk of new-onset AF in patients with T2DM.
Thus, the aim of this hypothesis-generating study was to examine
whether early LSSYS impairement may predict subsequent develop-
ment of AF in T2DM patients with preserved LV ejection fraction and
without ischemic heart disease.
2. Materials and methods
2.1. Patients
In this exploratory analysis, we followed for 2 years a sample of
180 outpatients with T2DM, who were consecutively selected among
those regularly attending our diabetes clinic during a period of
18 months. For this study, we had excluded patients with 1) a history
of ischemic heart disease (IHD), chronic heart failure or LV systolic
dysfunction (deﬁned as LV ejection fraction b50%); 2) a history of
moderate-to-severe valvular heart diseases, paroxysmal/persistent
atrial ﬁbrillation or ﬂutter; 3) a pacemaker or implantable cardio-
verter deﬁbrillator; 4) a history of alcohol abuse, cirrhosis, cancer and
overt nephropathy; and 5) a poor and unstable glycemic control.
Patients who were taking antiarrhythmic agents were also excluded
from the study.
As consequence of this selection, 189 outpatients with T2DMwere
initially screened. All these patients underwent exercise stress
myocardial perfusion scintigraphy (as detailed below) in order to
exclude the presence of asymptomatic myocardial perfusion defects
(which were detected in 9 patients); thus, a sample of 180 patients
with T2DM was followed-up for subsequent 2 years and included in
the present analysis. All the 180 patients were periodically seen at the
diabetes clinic (every 6–8 months) for medical examinations of
glycemic control, and chronic diabetic complications; standard
12-lead electrocardiograms (ECG) were also performed twice per
year. The ascertainment at the end of the 2-year follow-up period was
100% for the whole sample.
The local ethics committee approved the study protocol. All
participants gave their informed consent for participation in this research.
2.2. Clinical and laboratory data
Body mass index (BMI) was calculated by dividing weight in
kilograms by height in meters squared. A physician measured blood
pressure with a mercury sphygmomanometer after patients had been
seated quietly for at least 5 min. Patients were considered to have
hypertension if their blood pressure was ≥140/90 mmHg or if theywere taking anti-hypertensive drugs. Information on smoking, alcohol
consumption and medication use was obtained from all patients via
interviews during medical examinations.
Venous blood samples were drawn in the morning after an overnight
fast. Serum lipids, creatinine and other biochemical blood measurements
were determined using standard laboratory procedures. LDL-cholesterol
was calculatedusing the Friedewald's equation. HemoglobinA1c (HbA1c)
was measured using an automated high-performance liquid chromatog-
raphy analyzer; the upper limit of normal for our laboratory was 5.6%.
Estimated glomerular ﬁltration rate (eGFR) was calculated by the
four-variable Modiﬁcation of Diet in Renal Disease study equation
(Stevens, Coresh, Greene, & Levey, 2006).
In all patients, the presence of microvascular diabetic complica-
tions was also recorded. At baseline, nephropathy was deﬁned as the
presence of eGFR b60 mL/min/1.73 m2 or abnormal albuminuria (i.e.,
an albumin-to-creatinine ratio ≥ 30 mg/g creatinine on a morning
spot urine sample) (Stevens et al., 2006). A single ophthalmologist
diagnosed diabetic retinopathy using fundoscopy after pupillary
dilation. The presence of lower-extremity sensory neuropathy was
recorded by the medical history and examination and by the use of
biothesiometer Vibrotest.
2.3. Echocardiography
A trans-thoracic echocardiographic Doppler evaluation with
spectral tissue Doppler analysis (Vivid 7, GE Vingmed, Horten,
Norway) were performed in all patients by a single experienced
cardiologist, who was blinded to participants' details. Conventional
echocardiography was used to measure LV diameters, wall thickness,
and mass according to standard criteria. LV end-diastolic and
end-systolic volumes and ejection fraction (EF) at rest were measured
at the apical 4-chamber and 2-chamber views by modiﬁed Simpson
rule (Lang et al., 2015). LA minimum volume (LAVmin) was
determined at the end of LV diastole at the ﬁrst frame after mitral
valve closure and LAmaximum volume (LAVmax) wasmeasured at the
end of LV systole right before mitral valve opening from the apical
4-chamber and 2-chamber views using the modiﬁed Simpson rule
(Lang et al., 2015). LAV index minimum (LAVImin) and maximum
(LAVImax) were calculated as LA volumes divided with the body
surface area. Pulsed-wave Doppler was used to measure trans-mitral
peak early diastolic velocity (E), peak late diastolic velocity (A) and
E-wave deceleration time (Dte). Pulsed-wave tissue Doppler echo-
cardiography of the septal and lateral mitral annulus was used to
measure the systolic (s') and early peak (e’) diastolic tissue velocities,
and themean values of septal and lateral annulusmeasurements were
used for analysis. The ratio of trans-mitral E-wave velocity to e’ was
calculated as previously proposed (Nagueh, Middleton, Kopelen,
Zoghbi, & Quiñones, 1997; Sohn et al., 1997).
Myocardial deformation measurements were also performed
off-line in patients with adequate apical windows with the use of a
standard EchoPac PC workstation application (GE Healthcare, Wis-
consin, USA) for two-dimensional speckle-tracking myocardial strain
analysis. Global longitudinal strain and strain rate curves were
obtained including all six LV myocardial segments from 4-chamber,
2-chamber, and long-axis apical views (Reisner et al., 2004). The
average values of peak systolic longitudinal strain and peak systolic
strain rate from the 3-apical views were calculated as global
longitudinal strain (LSSYS) and global strain rate (SRSYS), respectively.
Similarly, the global strain rate during the early (SRE) and late (SRL)
phase of diastole was also calculated. The ratio of trans-mitral E-wave
velocity to SRE as an index of LV ﬁlling pressure was calculated as
previously proposed (Wang, Khoury, Thohan, Torre Amione, &
Nagueh, 2007). Standard echocardiographic views were obtained
using frequency, depth, and sector width adjusted for frame-rate
optimization (between 60 and 100 fps). In a previous study (Bonapace
et al., 2011), we have shown that when tissue Doppler imaging signals
Table 1
Baseline clinical and biochemical characteristics of patients with T2DM stratiﬁed by








Sex (male/female) (n) 124/42 11/3 0.74
Age (years) 68.8 ± 6.2 68.9 ± 5.1 0.97
Weight (kg) 82.1 ± 14.9 85.7 ± 12.1 0.37
BMI (kg/m2) 28.6 ± 4.7 29.3 ± 3.9 0.60
Diabetes duration (years) 15.2 ± 10.1 12.4 ± 7.8 0.32
Systolic blood pressure (mmHg) 142.2 ± 16.7 142.8 ± 14.3 0.77
Diastolic blood pressure (mmHg) 77.3 ± 8.8 82.1 ± 4.7 b0.05
Pulse pressure (mmHg) 66.8 ± 14.1 60.7 ± 13.7 0.11
Fasting glucose (mmol/l) 8.2 ± 2.3 7.8 ± 1.2 0.62
Hemoglobin A1c (%) 7.2 ± 1.2 7.6 ± 1.0 0.34
Total cholesterol (mmol/l) 4.45 ± 0.9 4.70 ± 1.3 0.34
HDL cholesterol (mmol/l) 1.25 ± 0.3 1.24 ± 0.3 0.91
Triglycerides (mmol/l) 1.61 ± 0.7 1.65 ± 0.5 0.83
Estimated GFRMDRD (ml/min/1.73 m2) 80.1 ± 21.2 74.5 ± 24.8 0.35
Current smokers (%) 36.1 57.1 0.28
Hypertension (%) 83.7 85.7 0.84
Diabetic retinopathy (%) 16.8 14.2 0.79






eGFRMDRD b 60 ml/min/1.73 m2 ±
albuminuria
11.5 28.6
Oral hypoglycemic drug users (%) 78.3 57.1 0.09
Insulin users (%) 44.6 42.8 0.90
ACE-inhibitors/ARB users (%) 41.6 78.6 b0.01
Calcium-channel blocker users (%) 40.4 35.7 0.73
Diuretic users (%) 41.6 57.1 0.26
Beta-blocker users (%) 21.7 35.7 0.25
Statin users (%) 77.7 85.7 0.48
Sample size, n = 180. Data are expressed as means ± SD or percentages.
ACE-I, angiotensin converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin
II receptor blocker; BMI, body mass index; eGFRMDRD, estimated glomerular ﬁltration
rate (by the MDRD study equation).
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differences (±SD) in tissue velocities within the same observer
were 0.10 ± 0.02 cm/s for s' velocity and 0.19 ± 0.17 cm/s for e’
velocity, respectively (p = 0.73 for all differences). No signiﬁcant
differences were also found in the intra-observer and inter-observer
variabilities for LSSYS (0.79 ± 0.60% and 1.07 ± 0.80%), SRSYS
(0.08 ± 0.04 s−1 and 0.11 ± 0.07 s−1), and SRE (0.08 ± 0.06 s−1
and 0.12 ± 0.08 s−1) (p-values not signiﬁcant for all differences).
Effective arterial elastance was estimated as end-systolic pressure
divided by stroke volume (Kelly et al., 1992) and systemic vascular
resistance index by mean arterial pressure÷cardiac index × 80.
2.4. Myocardial perfusion scintigraphy
At baseline, stress and rest studies were done in all patients in a
two-day (2 × 370 MBq) protocol using Technetium-99 m
2-methoxy-isobutyl-isonitrile (99mTc-MIBI), according to local stan-
dardized routine. During a bicycle exercise test, 99mTc-MIBI was
injected at peak symptom-limited exercise testing. Bicycle exercise
was performed following the Bruce protocol; ECG and blood pressure
were recorded at rest and every 2 min during exercise and recovery.
370 MBq of 99mTc-MIBI was injected at rest and at peak exercise.
Images were acquired 60 min after the injection of radiopharmaceu-
tical drug on the two phases (at baseline and after bicycle ergometry
test). The single photon emission computed tomography (SPECT)
acquisition protocol usually started with the resting part, followed by
SPECT at stress the day after. SPECT was performed using a
double-head gamma-camera (Millennium MG, GE) equipped with
two scintillation detectors, angled 90°, with high resolution and low
energy parallel-hole collimators. The protocol included 32 projec-
tions, 40-s projections, and 12 frames per cycle used in association
with a 15% window centered on the 140-keV photo peak of
99mTc-MIBI.
2.5. Diagnosis of incident atrial ﬁbrillation
At baseline, all patients were free from AF as documented by a
standard 12-lead ECG. A 24-h Holter monitor examination was not
routinely performed either at baseline or during the follow-up period.
During the follow-up, patients were diagnosed with AF if AF or atrial
ﬂutter was present on a standard ECG that was obtained either from a
routine clinic examination in our diabetes clinic (i.e., a standard ECG
was performed twice per year in all patients) or from reviewing
hospital and physician charts from all patients. The diagnosis of AF
was conﬁrmed in affected patients by an experienced cardiologist,
who was blinded to clinical details of participants.
2.6. Statistical analysis
Data are expressed as means ± SD or frequencies. Differences in
baseline clinical/biochemical characteristics and echocardiographic
parameters among patients stratiﬁed by their status of incident AF at
follow-up were tested with the unpaired Student's t-test for normally
distributed variables, the Mann–Whitney test for non-normally
distributed variables, and the chi-squared test for categorical variables
(Tables 1 and 2). Binary logistic regression analysis was used to
examine the association between clinical/biochemical and echocar-
diographic parameters and the risk of incident AF, whichwas included
as the dependent variable. For prediction of incident AF, four
forced-entry logistic regression models were performed (Table 3).
Covariates included in these multivariate regression models were
chosen as potential confounding factors based either on their
signiﬁcance in univariate analyses or on their biological plausibility
(e.g., age, sex and duration of diabetes). We performed a logistic
regression analysis instead of a time-dependent Cox regression
analysis since in presence of a small number of events atime-to-event type of analysis, such as Cox regression, ismore susceptible
tobias thanbinary logistic regression analysiswhenadjusted for predictor
variables since there is the potential for a marked difference in time to
event in the exposed versus the unexposed group. Indeed, we tested by
graphical technics and likelihood ratio statistics that in our study the
proportional-hazards assumption of Cox regression analysis was not
satisﬁed. In addition, since the precise time to event (AF) may not be
known in some people with asymptomatic AF (e.g., in patients with slow
AF), we undertook logistic regression analysis. P-values b0.05 were
considered statistically signiﬁcant.
3. Results
Among the 180 patients included in the study (mean age: 68.9 ±
6 years, mean duration of diabetes 15.3 ± 10 years), 14 (7.8%)
patients developed incident AF during the 2-year follow-up period.
At baseline, no patients had mitral stenosis, bicuspid aortic valve
disease or aortic stenosis. In addition, a few patients had mild aortic/
mitral regurgitation, but none of them had moderate or severe aortic
and mitral regurgitation. By study design, all patients had normal
myocardial perfusion scintigraphy and preserved LVEF.
Table 1 shows the baseline clinical and biochemical characteristics
of patients stratiﬁed by their status of incident AF at follow-up. At
baseline, patients who developed AF at follow-up had higher diastolic
blood pressure values and were more likely to be treated with
anti-hypertensive drugs compared with those who did not. Notably,
age, sex, diabetes duration, BMI, systolic blood pressure, pulse
pressure, hypertension, lipids, smoking, HbA1c, diabetes treatment
and microvascular complication status did not signiﬁcantly differ
between the two groups.
Table 2
Baseline echocardiographic characteristics of patients with T2DM stratiﬁed by their








LV end-diastolic volume (ml) 103.1 ± 23.4 115.5 ± 58.2 0.12
LV end-systolic volume (ml) 38.3 ± 15.1 48.8 ± 46.6 0.07
LV ejection fraction (%) 63.7 ± 7.9 62.9 ± 12.1 0.72
LV mass index (g/m2) 114.0 ± 21.6 133.8 ± 46.7 b0.01
LAVI max (ml/ m2) 32.6 ± 10.5 37.5 ± 21.6 0.13
LAVI min (ml/ m2) 16.1 ± 8.2 22.3 ± 19.4 b0.05
E/A ratio 0.73 ± 0.15 0.81 ± 0.25 0.07
Dte (ms) 264.4 ± 65 258.5 ± 69 0.59
s' velocity (cm/s) 9.2 ± 1.8 8.5 ± 2.1 0.25
e’ velocity (cm/s) 7.9 ± 1.9 7.1 ± 1.8 0.16
E/ e’ ratio 8.8 ± 2.8 9.6 ± 3.4 0.32
IVRT (ms) 84.3 ± 15.1 94.6 ± 17.9 b0.05
SAC (mmHg/ml) 1.01 ± 0.28 1.09 ± 0.28 0.35
SVR index (dyne/s/cm5) 2320.4 ± 745.5 2427.2 ± 770.1 0.63
LSSYS (%) −16.2 ± 2.6 −12.6 ± 4.0 b0.001
SRSYS (s−1) −1.02 ± 0.22 −0.93 ± 0.19 0.14
SRE (s−1) 1.08 ± 0.26 0.89 ± 0.22 0.01
SRL (s−1) 1.16 ± 0.32 0.83 ± 0.21 b0.001
E/SRE ratio (m) 0.64 ± 0.21 0.79 ± 0.34 b0.05
Sample size, n = 180. Data are expressed as means ± SD.
AF, atrial ﬁbrillation; LAVI left atrial volume index; IVRT, isovolumetric relaxation time;
LSSYS, global longitudinal strain; LV, left ventricular; SAC, systemic arterial compliance;
SVR, systemic vascular resistance; SRSYS, global strain rate; SRE, global diastolic strain
rate during early phase of diastole; SRL, global diastolic strain rate during late phase of
diastole.
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participants stratiﬁed by their status of incident AF at follow-up. At
baseline, patients who developed AF at follow-up had higher indexed
LV mass and larger LAVI compared with those who did not. They also
had longer IVRT. Among the global LV strain and strain rate
measurements at baseline, patients who developed AF at follow-up
had lower LSSYS, lower SRE, lower SRL and higher E/SRE ratio compared
with those who did not. LV volumes, LVEF, E/A ratio, Dte, s' velocity, e’
velocity, E/e’ ratio, SVR index and SAC did not differ between the two
groups of patients.
Table 3 shows the independent predictors of new-onset AF in four
multivariate logistic regressionmodels. Impaired LSSYS was associated
with an approximately 1.4-fold increased risk of incident AF after
adjustment for age, sex, duration of diabetes and SRL (model 1).
Further adjustment for either LV mass index and LAVI (model 2) or E/
SRE ratio (model 3) did not weaken the strong association between
impaired LSSYS and AF risk. Results remained unchanged when we
adjusted for age, sex, duration of diabetes, HbA1c, hypertension, BMI
and SRL (model 4). Almost identical results were also found in moreTable 3
Multivariate logistic regression analyses: independent predictors of incident atrial ﬁbrillatio
Multivariate logistic regression models
Model 1 p Model 2
Age (years) 1.00 (0.89–1.12) 0.99 1.00 (0.89–1.12)
Sex (male) 0.18 (0.02–1.77) 0.22 0.35 (0.04–3.19)
Diabetes duration (years) 1.01 (0.94–1.08) 0.89 0.99 (0.93–1.08)
LSSYS (%) 1.43 (1.06–1.91) b0.01 1.63 (1.17–2.27)
SRL (s−1) 0.18 (0.01–1.38) 0.08 Not included
LAVI min (ml/m2) Not included – 0.96 (0.88–1.05)
LV mass index (g/m2) Not included – 1.02 (0.99–1.06)
E/SRE ratio (m) Not included – Not included
HbA1c (%) Not included – Not included
Hypertension (yes vs. no) Not included – Not included
BMI (kg/m2) Not included – Not included
Sample size, n = 180. Data are expressed as odds ratios ±95% conﬁdence intervals (in par
Incident AF was the dependent variable in all multivariate logistic regression models.parsimonious logistic regression models when we removed age, sex
and duration of diabetes (that were included in the above-mentioned
models on the basis of their biological plausibility but did not
signiﬁcantly differed at baseline between patients who developed AF
at follow-up and those who did not, as shown in Table 1) from the list
of covariates included in all these multivariate regression models.
4. Discussion
The main ﬁnding of this pilot, prospective study is that impaired
LSSYS was associated with an increased risk of new-onset AF over a
2-year follow-up period in T2DM patients with preserved LVEF and
without IHD at baseline. Notably, this association was independent of
multiple clinical and echocardiographic risk factors for AF. This ﬁnding
suggests that early LSSYS impairement is among the ﬁrst myocardial
alterations that predispose this particularly high-risk patient popula-
tion to subsequent development of AF.
Impaired LSSYS is an emerging, powerful predictor of cardiovascu-
lar morbidity and mortality in patients without clinical LV systolic
disfunction (Russo et al., 2014; Stanton et al., 2009), in patients with
chronic systolic heart failure (Motoki et al., 2012) and in those with
persistent/permanent AF (Su et al., 2013). Moreover, impaired LSSYS is
associated with hypertension, obesity, subclinical atherosclerosis,
increased large elastic artery stiffness and mitral regurgitation (Di
Salvo et al., 2006; Kamperidis, Marsan, Delgado, & Bax, 2016; Russo
et al., 2011, 2013), which are all established risk factors for AF
(Anonymous, 2014).
Recently, Russo et al. ﬁrstly reported that impaired LSSYS was also
signiﬁcantly associated with an increased risk of new-onset AF among
elderly participants from the population-based Northern Manhattan
Study. Interestingly, in this study the prognostic value of LSSYS for
incident AF was incremental over established risk factors and LAVI
(Russo et al., 2015).
To our knowledge, this is the ﬁrst prospective study to show that
impaired LSSYS was a powerful predictor of new-onset AF also in
people with T2DM, i.e., a group of individuals in which AF
(Anonymous, 2014; Du et al., 2009; Huxley et al., 2011; Movahed
et al., 2005; Ostgren et al., 2004) and early LSSYS impairement (Nakai
et al., 2009; Ng et al., 2009) are two highly prevalent pathologic
conditions. An early LSSYS impairement in T2DM patients without
obstructive IHD may be, at least in part, due to coexisting coronary
microvascular dysfunctions or myocardial perfusion defects
(Marciano et al., 2012) as well as to increased myocardial ﬁbrosis,
which is a known marker of diabetic cardiomyopathy (Kang et al.,
2008) that may lead to early LSSYS impairement occurring even before
the appearance of LV diastolic dysfunction. In fact, early LSSYS
impairement may exist despite normal LV diastolic function in
patients with T2DM, indicating that diastolic dysfunction should notn in T2DM patients.
p Model 3 p Model 4 p
0.99 1.00 (0.89–1.13) 0.99 1.00 (0.88–1.13) 0.99
0.41 0.18 (0.01–1.78) 0.14 0.20 (0.02–1.94) 0.16
0.97 1.00 (0.93–1.08) 0.86 1.00 (0.93–1.08) 0.93
b0.005 1.47 (1.07–2.02) b0.01 1.41 (1.03–1.90) b0.05
– 0.05 (0.01–1.27) 0.07 0.06 (0.01–1.26) 0.07
0.38 Not included – Not included –
0.22 Not included – Not included –
– 0.33 (0.01–8.19) 0.50 Not included –
– Not included – 1.27 (0.72–2.24) 0.41
– Not included – 1.17 (0.11–12.6) 0.90
– Not included – 1.01 (0.83–1.20) 0.99
enthesis) as assessed by multivariate logistic regression analysis.
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cardiomyopathy (Ernande et al., 2011).
Interestingly, both in our study and in that of Russo et al. (2015)
LVEF did not provide any additional prognostic information for risk of
incident AF. This is likely due to the fact that at the early stage of
diabetic cardiomyopathy the radial contractility may compensate for
reduced longitudinal contractility (Fang, Leano, & Marwick, 2004).
This compensatory mechanismmay also explain the predictive role of
LV fractional shortening (a measure of radial systolic function) on risk
of new-onset AF observed in a previous study (Vaziri, Larson,
Benjamin, & Levy, 1994).
It is known that in hypertensive patients with no other major
predisposing conditions, the risk of new-onset AF increases progres-
sively with increasing cardiac mass (Verdecchia et al., 2003). Also in
our study, we observed that increased cardiac mass at baseline was
associated with a higher risk of new-onset AF. In our study, obviously,
it is not easy to discriminate whether the increased cardiac mass is
mainly related to coexisting hypertension or diabetes per se.
However, the lack of any signiﬁcant differences in the frequency of
hypertension and in total vascular load (both in terms of arterial
stiffness and in terms of systemic vascular resistance as shown in
Table 1) we observed between the two groups of patients suggests
that the observed increase in LV mass may be, at least in part,
dependent on diabetes per se.
Also minimum LAVI was a signiﬁcant, positive predictor of
new-onset AF in our diabetic population. This ﬁnding conﬁrms
previous results in older patients without heart valve disease, in
which minimum LAVI was found to be superior to maximal LAVI in
predicting the risk of new-onset AF, irrespective of LVEF and diastolic
dysfunction (Fatema et al., 2009). It is important to underline that a
close interplay does exist between LA volume and ventricular systolic
performance throughout the cardiac cycle (Barbier, Solomon, Schiller,
& Glantz, 1999). Indeed, LA volume is inﬂuenced not only by the atrial
characteristics but also by the LV end-systolic volume and the descent
of LV base during the systole (Hoit, 2014). A signiﬁcant association
between impaired LSSYS and LA volume and function was in fact
described (Russo et al., 2012). However, it is also important to
underline that in our study impaired LSSYS was the only signiﬁcant
predictor of new-onset AF after adjusting for LV mass and diastolic
function parameters, such as LAVI and E/SRE ratio, thus further
supporting an important role of early LSSYS impairement in predicting
the risk of new-onsetAF in T2DM. It is reasonable to assume that impaired
LSSYS is the most early marker of disease related to coexisting coronary
microvascular dysfunction and subclinical atherosclerosis that involve
both the left ventricle and the left atrium, and that predisposes to the
developmentofﬁbrotic changes that favormyocardial electrical instability
and subsequent development of AF. In fact, the existence of an atrial
diabetic cardiomyopathy paralleling an LV diabetic cardiomyopathy,
irrespective of coexisting loading conditions, was also recently suggested
(Bonapace et al., 2015; Kadappu et al., 2012).
Our study has some important limitations that should be
mentioned. Firstly, there were a relatively small number of clinical
events during the 2-year follow-up period (i.e., a total of 14 (7.8%)
cases of incident AF) and, therefore, the results of our multivariate
regression analyses should be interpreted with some caution.
Secondly, we could not assess the impact of temporal changes in
LSSYS on subsequent development of AF. Finally, since a 24-h Holter
monitor examination was not routinely performed, the case ascer-
tainment of AF might have been incomplete in this study, especially if
patients had some episodes of asymptomatic paroxysmal AF.
Although a standard ECG was performed twice a year in all patients
and no patients were treated with antiarrhythmic drugs at baseline,
cases of asymptomatic paroxysmal AF may have been missed, so
reducing the power to detect some signiﬁcant associations.
Despite these limitations, our study has important strengths that
include its prospective design, the complete nature of the dataset, theclose follow-up, the ECG measurements twice per year, and the
review of hospital and physician charts from all patients over the
follow-up that reduce the potential for missed or misclassiﬁed study
outcome(s). In addition, none of our patients had myocardial
perfusion defects on myocardial scintigraphy; we believe that the
inclusion of such patients would have confounded the interpretation
of the results of this study.
In conclusion, our pilot prospective study is the ﬁrst to show a
strong association between early LSSYS impairment and increased risk
of incident AF in T2DMpatients with preserved LVEF andwithout IHD.
Notably, this association was independent of multiple clinical and
echocardiographic risk factors for AF. However, the ﬁndings of this
hypothesis-generating study need to be prospectively validated in
larger cohorts of patients with T2DM.
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